Pacira BioSciences PCRX

Pacira BioSciences Q3 FY26: revenue $176.7M, down 2%; diluted EPS $0.70

Form
10-Q
Filed
Period
Importance
Notable

The plain-English summary is being written. The app sends it the moment it is ready.

Get an email when Pacira BioSciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

Data on this page was fetched . The filing on SEC.gov is the record.